Medical Industry Feature

Informações:

Sinopsis

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

Episodios

  • Improving Tolerance with Blenderized Whole Food Tube Feeding Formulas

    27/10/2023

    Host: Jennifer Caudle, DO Guest: Katherine Bennett, MPH, RD, CLEC Caregivers and children often face challenges when trying to find a formula that’s well-tolerated, and the burden of feeding intolerance extends to the healthcare system as well. Find out how blenderized whole food tube feeding whole food tube feeding formulas like Compleat Organic Blends can help address those challenges and benefit pediatric patients with Dr. Jennifer Caudle and Ms. Katherine Bennett, a registered dietitian at the Children’s Hospital of Orange County in California. All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland. ©2023 Nestlé

  • Integrating Multicancer Early Detection into Clinical Care

    24/10/2023

    Host: Sana Raoof, MD, PhD Guest: Candace T. Westgate, DO, MPH, FACOG Guest: Mylynda Massart, MD, PhD The last five years have seen exciting progress with liquid biopsy tests, with one of them being a screening tool for multi-cancer early detection that looks for methylation patterns that can detect more cancers earlier, even before symptoms appear.1,2 Learn how you can incorporate this screening tool into clinical practice with Drs. Sana Raoof, Candace Westgate, and Mylynda Massart. Dr. Raoof is a physician scientist at Memorial Sloan Kettering Cancer Center, Dr. Westgate is the Medical Director of the AHEAD Program and Chief of Staff at Adventist Health Saint Helena in Northern California, and Dr. Massart is the Founder and Director of the UPMC’s Primary Care Precision Medicine Center. References: Nadauld LD, McDonnell CH 3rd, Beer TM, et al. The PATHFINDER Study: Assessment of the implementation of an investigational multi-cancer early detection test into clinical practice. Cancers (Basel

  • Cancer Screenings: The Impacts of Early Detection Technology

    24/10/2023

    Host: Jennifer Caudle, DO Guest: Sana Raoof, MD, PhD There’s a multi-cancer early detection test available that uses a targeted methylation, next-generation sequencing-based assay to detect and analyze cell-free DNA in the bloodstream, deploy machine learning to detect a cancer signal, and predict the likely origin of the signal.2 Explore the science behind this advancement that provides the highest specificity of any cancer screening tool1 with Dr. Jennifer Caudle and Dr. Sana Raoof, physician scientist at Memorial Sloan Kettering Cancer Center. References: Nadauld LD, McDonnell CH 3rd, Beer TM, et al. The PATHFINDER Study: Assessment of the implementation of an investigational multi-cancer early detection test into clinical practice. Cancers (Basel). 2021;13(14):3501. Published 2021 Jul 13. doi:10.3390/cancers13143501 Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV; CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

  • Neuroplasticity: A Potential Target for the Treatment of Depression

    10/10/2023

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Madhukar H. Trivedi, MD The brain is constantly changing as a result of experience, stress, emotional processing, learning, and memory.1 And neuroplasticity adds another layer to these approaches by focusing on what’s actually changing in the brain.2 Tune in with Dr. Charles Turck as he speaks with Dr. Madhukar Trivedi, Founding Director of the Center for Depression Research and Clinical Care and Chief of the Division of Mood Disorders at the University of Texas Southwestern Medical Center in Dallas, Texas. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63-77. Mateos-Aparicio P, Rodriguez-Moreno A. The impact of studying brain plasticity. Front Cell Neurosci. 2019;13:66. August 2023 US.UNB.X.23.00081

  • Addressing Hesitancy on Biosimilars: From Development to Clinical Practice

    14/09/2023

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jerome Goldschmidt, MD Despite the potential benefits of biosimilars, such as decreased costs for patients, healthcare systems, and payers,1,2 their uptake in U.S. clinical practice has lagged behind that of the E.U.2 That’s why Dr. Jerome Goldschmidt joins Dr. Charles Turck to address common misconceptions surrounding biosimilars and examine key points in their development, manufacturing, and approval process. Dr. Goldschmidt is a medical oncology specialist practicing at Blue Ridge Cancer Care, and he’s also affiliated with the U.S. Oncology Network in Blacksburg, Virginia. References:1. IQVIA. Biosimilars in the United States 2023–2027: Competition, Savings, and Sustainability. 2023. Accessed June 20, 2023. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2023-20272. Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health ca

  • From Monoamines to Neurocircuits: Our Evolving Understanding of Depression

    30/08/2023

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Joseph F. Goldberg, MD Our understanding of depression has evolved over the past several decades, leading us to some potential new treatment options that focus on neuroplasticity. Learn more about the history of depression treatment approaches and the emerging concept of neuroplasticity with Dr. Charles Turck and Dr. Joseph Goldberg, Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City. August 2023 US.UNB.X.23.00071

  • From Heterogeneity Comes New Insights: Exploring the Role of T Cells & OX40 Signaling in Atopic Dermatitis

    29/08/2023

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jonathan Silverberg, MD, PhD, MPH Atopic dermatitis is more than a disease of the skin. It’s a complex and heterogeneous inflammatory disease mediated by multiple T-cell–driven inflammatory pathways, like the OX40 pathway, leading to chronic and persistent symptoms and significant burden.1-4 Explore the heterogeneity of atopic dermatitis and the importance of OX40 signaling in disease pathogenesis with Dr Charles Turck and Dr. Jonathan Silverberg, Professor and Director of Clinical Research and the Director of Patch Testing at George Washington University School of Medicine and Health Sciences. References: Silverberg JI. Clinical Management of Atopic Dermatitis. 1st ed. 2018. Ratchataswan T, et al. J Allergy Clin Immunol Pract. 2021;9:1053-1065. Weidinger S, et al. Nat Rev Dis Primers. 2018;4:1. De Bruyn Carlier T, et al. J Autoimmun. 2021;120:102634. ©2023 Amgen Inc. All rights reserved. USA-451-80031 8/23

  • A Case for 4F-PCC: Mortality & Safety Data vs. Plasma

    28/07/2023

    Host: Jennifer Caudle, DO Guest: Michelle Kincaid, MD The largest study to date on 4F-PCC was conducted as an FDA postmarketing requirement in partnership between Kaiser Permanente and CSL Behring. The purpose of this long-term study was to compare the 45-day risk of thromboembolic events and all-cause mortality in adults with warfarin-associated major bleeding after treatment with KCENTRA®, Prothrombin Complex Concentrate (Human), or plasma. Take a deep dive into the data with Dr. Jennifer Caudle as she speaks with Dr. Michelle Kincaid, Trauma Surgeon and Director of Surgical Critical Care at Ohio Health Grant Medical Center in Columbus.

  • Vaccine Viewpoint: Looking at Cell-Based Technology for Flu Prevention

    24/07/2023

    Host: Jennifer Caudle, DO Guest: Ravi Jhaveri, MD Influenza vaccines have prevented between 39,000 and 105,000 hospitalizations and between 3,700 and 9,800 deaths each year over the last 10 years in the United States alone.1 But many challenges still exist in the traditional egg-based influenza vaccine manufacturing process. To explore how cell-based vaccines, an option that uses an alternative manufacturing approach, could help address those challenges and the overall influenza burden, Dr. Jennifer Caudle speaks with Dr. Ravi Jhaveri, Division Head of Pediatric Infectious Diseases at the Ann & Robert H. Lurie Children's Hospital of Chicago. References:1. Centers for Disease Control and Prevention. Past seasons estimated influenza disease burden averted by vaccination. https://www.cdc.gov/flu/vaccines-work/past-burden-averted-est.html. Accessed April 8, 2022. USA-QIVc-23-0038 06/23

  • Inflammation Biosimilars: Examining the Totality of Evidence for Approval

    17/07/2023

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Gil Melmed, MD, MS The inflammation biosimilar development process uses a stepwise approach with increasing certainty to generate the totality of evidence, which demonstrates the safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed.1,2 Dive further into the role of totality of evidence in the inflammation biosimilar development and approval process with Dr. Gil Melmed, Director of Inflammatory Bowel Disease Clinical Research at the Cedars-Sinai and Professor of Medicine at Cedars-Sinai and at the David Geffen School of Medicine at University of California, Los Angeles. Dr. Melmed was compensated for participating in this program. References: US Food and Drug Administration. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance for Industry. Published online April 2015. Accessed March 22, 2023. https://www.fda.gov/media/

  • Enhancing Your Aesthetic Skillset: A New Training and Educational Hub

    07/07/2023

    Host: Jennifer Caudle, DO Guest: Jeran Wadlow Guest: Josh Elmassian, MBA Allergan Medical Institute® has taken a personalized approach to training HCPs in medical aesthetics with the launch of AMI Online. Discover multiple online courses spanning the Allergan Aesthetics portfolio, including content on JUVÉDERM® VOLUX® XC. Experience how AMI Online’s evidence-based and progressive training curricula can educate and empower the aesthetics community. Join Dr Jennifer Caudle as she speaks with Jeran Wadlow, Associate Director, Digital at Allergan Medical Institute® in Irvine, California, and Josh Elmassian, Director of JUVÉDERM® US Commercial Business and Marketing at Allergan Aesthetics, in Irvine, California. © 2023 AbbVie. All rights reserved. JUVÉDERM and its design are trademarks of Allergan Holdings France SAS, an AbbVie company, or its affiliates. All other trademarks are the property of their respective owners. PRT162857 06/23

  • Letters from the Heart: People Should Know About Lp(a)

    22/06/2023

    It’s estimated that 20 percent of the world’s population has elevated Lp(a) greater than 50 milligrams per deciliter. Lp(a) is an independent, genetic, and causal risk factor for atherosclerotic cardiovascular diseases. For more insights, tune into this episode sponsored by Novartis. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623

  • Understanding Lp(a): Clinical Implications of an Underrecognized Genetic Dyslipidemia

    22/06/2023

    Guest: Santica Marcovina, PhD, ScD Lipoprotein(a), or Lp(a), is a unique apoB family lipoprotein that contains apo(a), which is a peculiar carbohydrate-rich protein covalently bound to an apoB lipoprotein. So are elevated Lp(a) levels a risk factor for atherosclerotic cardiovascular disease? Dive into this episode, sponsored by Novartis, to find out. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623

  • The ASCVD Journey With Lp(a): An ApoB-Family Lipoprotein

    22/06/2023

    Elevated lipoprotein(a), or Lp(a), is the most common inherited dyslipidemia that can drive the atherosclerotic process. So at what age does Lp(a) impact a patient’s life? To find out more, tune into this episode sponsored by Novartis. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623

  • Inherited Retinal Diseases, Genetic Testing, and What Eye Care Professionals Can Do Today

    21/06/2023

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Mark Pennesi, MD, PhD Approximately 165,700 people in the United States are affected by inherited retinal diseases (IRDs) and treatment options for these conditions are limited. So what role does genetic testing play in the patient journey of people living with IRDs? Join Dr. Charles Turck as he dives into this topic with Dr. Mark Pennesi, Professor of Ophthalmology and an IRD specialist affiliated with the Casey Eye Institute at the Oregon Health and Science University School of Medicine. ©Janssen Pharmaceuticals, Inc. 2023 05/23 cp-367503v1

  • Future Imaging Modalities in Spondyloarthritis

    18/05/2023

    Host: Ethan Craig, MD, MHS Guest: Walter Maksymowych, MB ChB, FRCP(C), FACP Appealing treatment options for patients with SpA might be right around the corner. So why do we need further imaging modalities and what do they have to offer? To give us a peek into the future, Dr. Ethan Craig is joined by Dr. Maksymowych, Professor of Medicine at the University of Alberta and Chief Medical Officer of CARE Arthritis. Dr. Craig and Dr. Bakewell are Novartis Consultants. 269162 03/23

  • The Role of Imaging in Determining Treatment Escalation in Spondyloarthritis

    04/05/2023

    Host: Ethan Craig, MD, MHS Guest: Catherine J. Bakewell, MD Disease activity in patients with spondyloarthritis (SpA) may be challenging to assess. So when should ultrasound and MRI be used to support clinical assessment? To provide us with more insights into this topic, Dr. Ethan Craig is joined by Dr. Catherine Bakewell, Rheumatologist at Intermountain Healthcare in Salt Lake City, Utah. Dr. Craig and Dr. Bakewell are Novartis Consultants. 269162 03/23

  • A Changing Paradigm for Cancer Screening: Exploring Surrogate Endpoints for an Urgent Public Health Concern

    24/04/2023

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Eric Klein, MD Cancer remains the second-leading cause of death in the U.S., creating an urgent need to detect cancer at earlier stages when outcomes are better. With the emergence of novel multi-cancer screening technologies, the potential public health impact may be substantial. Given these advances, is it time to rethink the way clinical trials are designed to assess the effectiveness of these screening technologies? Joining Dr. Charles Turck to discuss how we can utilize surrogate endpoints to evaluate the efficacy of cancer screening modalities is Dr. Eric Klein, a distinguished scientist at GRAIL.

  • Using MRI to Differentiate Axial Spondyloarthritis From Osteoarthritis

    20/04/2023

    Host: Ethan Craig, MD, MHS Guest: Walter Maksymowych, MB ChB, FRCP(C), FACP Over the last 20 year or so, magnetic resonance imaging (MRI) has changed how we evaluate axial spondyloarthritis (axSpA). But with a concerning rate of false-positive MRIs in recent data, it’s time to review where the field stands now, and update what the role of MRI seems to be in the diagnosis of spondyloarthritis (SpA). Join Dr. Ethan Craig in this discussion with an expert in SpA imaging, Dr. Maksymowych, Professor of Medicine at the University of Alberta and Chief Medical Officer of CARE Arthritis. Dr. Craig and Dr. Bakewell are Novartis Consultants. 269162 03/23

  • The Value of CINtec® PLUS Cytology Test in Cervical Cancer Screening

    14/04/2023

    Host: Jennifer Caudle, DO Guest: Tamera A. Paczos, MD, FACOG, FACP The utility of p16 and Ki-67 immunostaining in biopsies has helped lead to the development of dual staining in cytology specimens. So what do clinicians need to know about the dual stain cytology test? Take a deep dive into this topic as Dr. Jennifer Caudle is joined by Dr. Tamera A. Paczos, Vice President, Associate Chief Medical Officer with BioReference Laboratories. COBAS and CINTEC are trademarks of Roche.All other product names and trademarks are the property of their respective owners. 02/23

página 2 de 3